



NDA 21615/S-21  
NDA 21169/S-30  
NDA 21224/S-28

## SUPPLEMENT APPROVAL

Janssen Pharmaceuticals Inc.  
Attention: Tamara Mazza  
Associate Director, Global Regulatory Affairs  
1125 Trenton Harbourton Road  
Titusville, NJ 08560

Dear Ms. Mazza:

Please refer to your Supplemental New Drug Applications (sNDA) dated June 5, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Razadyne ER (galantamine HBr) extended-release 8 mg, 16 mg, 24 mg capsules  
Razadyne (galantamine HBr) 4 mg, 8 mg, 12 mg tablets  
Razadyne (galantamine HBr) 4 mg/ml oral solution

We acknowledge receipt of your amendments dated October 31, 2014, and February 4, 2015.

These Prior Approval Supplemental New Drug Applications propose changes to a number of sections of the Prescribing Information for Razadyne, including the addition of a new Warnings and Precautions subsection (5.1) describing the risk for serious skin reactions.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 21615/S-21  
NDA 21169/S-30  
NDA 21224/S-28  
Page 3

If you have any questions, call Teresa Wheelous, Sr. Regulatory Project Manager, at (301) 796-1161.

Sincerely,

*{See appended electronic signature page}*

Alice Hughes, MD  
Deputy Director for Safety  
Division of Neurology Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

ALICE HUGHES  
02/09/2015